New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sulfasalazine 500mg (sulfasalazine 500 mg added as 535 mg sulfasalazine with povidone) - tablet - 500 mg - active: sulfasalazine 500mg (sulfasalazine 500 mg added as 535 mg sulfasalazine with povidone) excipient: colloidal silicon dioxide magnesium stearate povidone pregelatinised maize starch - latest regulatory activity

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sulfasalazine 500mg (sulfasalazine 500 mg added as 535 mg sulfasalazine with povidone) - enteric coated tablet - 500 mg - active: sulfasalazine 500mg (sulfasalazine 500 mg added as 535 mg sulfasalazine with povidone) excipient: carnauba wax cellacefate colloidal silicon dioxide macrogol 20000 magnesium stearate povidone propylene glycol purified talc self-emulsifying glyceryl monostearate starch white beeswax - ulcerative colitis and crohn's disease adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis salazopyrin en tablets are indicated for rheumatoid arthritis which has failed to respond to nonsteroidal anti-inflammatory drugs (nsaids).

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - taliglucerase alfa 200 u (200 u deliverable, plus 6% overage) - powder for injection - 200 u - active: taliglucerase alfa 200 u (200 u deliverable, plus 6% overage) excipient: citric acid mannitol polysorbate 80 sodium citrate dihydrate - elelyso is indicated for long-term enzyme replacement therapy for adult and paediatric patients with a confirmed diagnosis of type 1 gaucher disease associated with at least one of the following: splenomegaly, hepatomegaly, anaemia, thrombocytopenia.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - clindamycin phosphate 178.22 mg/ml equivalent to clindamycin base 150 mg/ml;  ;  ;   - solution for injection - 600mg/4ml - active: clindamycin phosphate 178.22 mg/ml equivalent to clindamycin base 150 mg/ml       excipient: benzyl alcohol disodium edetate dihydrate hydrochloric acid sodium hydroxide water for injection - clindamycin phosphate has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: 1. upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - alprostadil 12.8ug equivalent to maximum dose of 10 mcg after reconstitution - powder for injection - 10 mcg - active: alprostadil 12.8ug equivalent to maximum dose of 10 mcg after reconstitution excipient: alfadex hydrochloric acid lactose monohydrate sodium citrate dihydrate sodium hydroxide benzyl alcohol water for injection - the treatment of erectile dysfunction in adult males. may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - alprostadil 25.6ug equivalent to maximum dose of 20 mcg after reconstitution - powder for injection - 20 mcg - active: alprostadil 25.6ug equivalent to maximum dose of 20 mcg after reconstitution excipient: alfadex hydrochloric acid lactose monohydrate sodium citrate dihydrate sodium hydroxide benzyl alcohol water for injection - the treatment of erectile dysfunction in adult males. may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - medroxyprogesterone acetate 150 mg/ml - injection (depot) - 150 mg/ml - active: medroxyprogesterone acetate 150 mg/ml excipient: hydrochloric acid macrogol 3350 methyl hydroxybenzoate polysorbate 80 propyl hydroxybenzoate sodium chloride sodium hydroxide - adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial or renal carcinoma

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - apixaban 2.5mg;  ;   - film coated tablet - 2.5 mg - active: apixaban 2.5mg     excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry yellow sodium laurilsulfate - eliquis is indicated for the prevention of venous thromboembolic events in adult patients who have undergone elective total hip or total knee replacement surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - apixaban 5mg;  ;   - film coated tablet - 5 mg - active: apixaban 5mg     excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry sodium laurilsulfate - eliquis is indicated for the prevention of venous thromboembolic events in adult patients who have undergone elective total hip or total knee replacement surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - glipizide 5mg - tablet - 5 mg - active: glipizide 5mg excipient: lactose monohydrate maize starch microcrystalline cellulose stearic acid - minidiab is an orally active hypoglycaemic sulphonylurea and is indicated as an adjunct to diet and exercise in the treatment of stable, mild to moderate, non-insulin dependent diabetes mellitus (type ii diabetes mellitus or niddm) without likelihood of ketosis, which cannot be adequately controlled by diet alone. treatment with minidiab is indicated only if a satisfactory reduction in blood sugar has not been achieved by other measures, e.g. conscientious adherence to the recommended diet, weight reduction in overweight patients, and adequate exercise. in certain patients receiving insulin, the concurrent use of minidiab allows a reduction in the daily dose of insulin.